Strategic vs Private Equity Veterinary Buyer: What Every Seller Needs to Know in 2026

Key takeaways

• There is one major strategic buyer and dozens of PE-backed buyers in the 2026 US vet market. Mars Veterinary Health — owner of VCA, Banfield, and BluePearl — is the only large-scale strategic acquirer. Every other significant consolidator operates under a private equity fund model with a defined exit requirement.
• The hold-period difference is the most important thing to understand. Strategic buyers own practices indefinitely. PE-backed buyers operate on a roughly 4-to-7-year fund lifecycle that ends with a sale, IPO, or recapitalization — and that timeline shapes every aspect of how they structure deals and run practices post-close.
• PE-backed offers commonly include rollover equity and earnouts; strategic offers typically do not. Understanding what portion of any offer is cash at closing vs. deferred or equity-contingent is the single most important factor in comparing offers from different buyer types.
• Brand handling diverges sharply between buyer types. Mars-affiliated buyers have integrated acquired practices under existing brands. PE-backed groups generally preserve local practice names across their portfolios.
• Neither buyer type reliably pays more — competition determines the outcome. The number you get from any buyer reflects the leverage they perceive in the conversation. A structured competitive process, not buyer type, is what moves the price.

There’s a question I hear over dinner with practice owners every few months, and it usually comes up after they’ve gotten a call from someone’s acquisition team and started doing their homework online. “I keep reading about strategic buyers and PE buyers. Does it actually matter which one I sell to?”

It matters. But not always in the direction people expect.

Most owners go into this thinking the buyer category — strategic or private equity — is the main variable. The right framing is the opposite. The buyer category tells you a lot about what life after the close looks like: hold period, brand decisions, what happens to your rollover equity, and whether you might get caught in a recapitalization event years down the road.

What it does not reliably predict is the headline number you receive. That comes from competition.

In 2026, the US veterinary practice acquisition market has one major strategic buyer and dozens of PE-backed groups. Mars Veterinary Health — the family-owned company behind VCA Animal Hospitals, Banfield Pet Hospital, and BluePearl Veterinary Partners — is the only large-scale strategic acquirer in the general-practice space. Every other significant group runs on a private equity model.

Knowing what that model means for you, as the seller, is what this piece is for. For the full picture of who’s buying and what they’re paying, we cover that in our veterinary practice consolidators guide and the PE pricing breakdown.

What separates a strategic buyer from a PE-backed buyer: A strategic buyer acquires practices as a permanent, long-term owner with no defined exit plan. A PE-backed buyer is funded by a private equity firm that raised a dedicated fund with a limited lifespan — typically 7 to 10 years for the fund itself, with a hold period for individual investments of roughly 4 to 7 years before the fund must return capital to its investors through a sale or recapitalization.

---

Who is actually buying in 2026, and which category do they fall into?

This is where most sellers get surprised.

Capstone Partners‘ April 2026 Pet Sector M&A Update logged 18 announced or completed veterinary and pet sector transactions in the year-to-date period, with the Vet & Health segment accounting for 9 of them. Strategic buyer activity climbed to 10 transactions in YTD 2026, compared to just 3 in the same period of 2025 — the broader market is pulling more strategic capital back into deal flow.

But in the veterinary-practice-specific segment, the picture is still heavily PE-dominated.

Mars Veterinary Health stands alone as the strategic buyer. Its US footprint spans VCA Animal Hospitals (roughly 1,000+ locations), Banfield Pet Hospital (a network of 1,100+ clinics primarily inside PetSmart stores), and BluePearl Veterinary Partners (specialty and emergency).

Mars, Inc. is a family-owned company — no PE fund, no exit clock. They acquire because veterinary care fits their permanent pet-industry strategy, not because they need to generate a return for limited partners by a specific date.

Every other major consolidator sits on the PE-backed side.

Consolidator	PE Sponsor	General acquisition focus
NVA	JAB Holdings	General practice, specialty/ER, broad US platform
Mission Pet Health	Shore Capital Partners	General practice GP; 930+ locations as of May 2026
VetCor	Harvest Partners + Oak Hill Capital	General practice, community hospitals
PetVet Care Centers	Ares Management	General practice GP platform
AmeriVet Veterinary Partners	AEA Investors + Abu Dhabi Investment Authority	General practice, multi-doctor practices
Thrive Pet Healthcare	TSG Consumer Partners	General practice and specialty
Alliance Animal Health	L Catterton	General practice
Heartland Veterinary Partners	Gryphon Investors	General practice
United Veterinary Care	TA Associates	General practice

Mission Pet Health is worth a specific note. It is the combined entity of Southern Veterinary Partners (SVP) and Mission Veterinary Partners (MVP), whose merger was announced in 2024 and formally closed late that year.

The unified Mission Pet Health brand launched publicly on July 21, 2025, at missionpethealth.com, per the company’s own press release. Shore Capital Partners, the Chicago-based PE firm, backs the platform.

As of May 2026, Mission Pet Health operates over 930 locations. It is among the most active acquirers in the market right now by location count.

Ethos Veterinary Health is technically within the NVA family — NVA acquired Ethos in 2022-2023, so sellers fielding Ethos outreach are engaging with NVA’s team. If you want a fuller picture of who owns what across the 40-plus active consolidators, that lives at our practice buyer directory.

---

What the PE fund lifecycle means for you as a seller

This is the part I spend the most time on when a vet asks me to walk through buyer types over dinner. The fund lifecycle is not abstract. It touches your deal directly.

When a PE firm raises a fund, limited partners — pension funds, endowments, family offices — commit capital for a defined window. The GP (the PE firm) deploys that capital into acquisitions, grows the portfolio, and must return the capital with gains before the fund closes.

That timeline drives the PE consolidator’s behavior at every stage.

The hold period for a PE-backed consolidator is typically 4 to 7 years. Some platforms run longer if market conditions are unfavorable; some compress shorter if a strong exit opportunity arises. But the fund has a clock, and that clock runs whether the market cooperates or not.

The exit options for a PE-backed consolidator are:

• Secondary buyout / recapitalization — the platform is sold to a new PE sponsor; the management team typically stays, and the clock resets under new ownership
• IPO — the consolidator goes public, giving existing investors and rollover-equity holders a path to liquidity
• Strategic sale — the platform is sold to a larger strategic buyer or another consolidator

VetCor, for example, completed a recapitalization that brought in Oak Hill Capital alongside Harvest Partners, a transaction that let early equity holders — including sellers who had rolled equity — realize value while the platform continued operating under the same management and brand. That is a typical PE lifecycle event, not an unusual one.

For you as a seller, the PE fund lifecycle matters in two ways.

First, if you are planning to stay involved in the practice for several years post-close, you need to know that ownership will likely change at least once during that window. The operating agreement and culture of your group may shift as a result.

That is worth factoring into how you evaluate a deal, not as a reason to avoid PE buyers, but as a dimension to understand and negotiate around.

Second, if you’re taking rollover equity — keeping a slice of ownership in the platform rather than taking all cash — your path to liquidity depends on the platform’s exit. We cover the mechanics of rollover equity and how to evaluate it in detail in our earnout and rollover equity guide.

The short version: rollover equity can be worth significantly more than the cash equivalent at exit, or it can be worth less depending on how the platform performs and when the exit happens. The terms you negotiate around lockup and liquidity milestones matter as much as the headline multiple.

Strategic buyers like Mars do not carry a fund clock. An acquisition by Mars is a permanent capital event — they are not planning to sell the platform to another buyer in 5 years.

That permanence changes the post-close relationship meaningfully. It also means that Mars’s deal structures are not built around a future exit event: you typically see less rollover equity in a Mars-type offer, and the expectation of continued ownership is off the table from day one.

---

How buyer type affects deal structure

The fund lifecycle difference shows up directly in how offers are written. Here’s the practical comparison.

PE-backed offer structure in 2026

Per industry M&A commentary from Dechert and Holland & Knight covering healthcare consolidation patterns, the typical PE-backed offer in this market allocates the majority of total deal value to cash at closing, with the remainder split across earnout, rollover equity, and occasional seller notes. The cash-at-closing portion commonly lands in the range of 60 to 80 percent of total headline value — but that range varies meaningfully with practice size, buyer type, and negotiation.

Earnouts — the portion of the price paid later, only if the practice hits agreed performance targets — in PE-backed offers commonly run 1 to 3 years, with the 2-year mark appearing most often. We cover earnout mechanics separately in our earnout guide.

A growing segment of PE-backed consolidators has shifted toward partnership models: the buyer acquires 60 to 80 percent of the practice, the seller retains 20 to 40 percent as direct equity in the practice entity itself (not just the platform), and a contractual put/call mechanism defines the buyout date and formula. That is meaningfully different from the pure rollover model and from a full acquisition.

The seller stays an owner of their own practice for a defined period.

Strategic buyer offer structure

Mars-type acquisitions generally run closer to full-purchase structures. Because there is no exit event to engineer around, there is less structural rationale for complex earnouts and rollover equity packages.

Offers from strategic buyers tend to be more straightforward on structure — closer to the purchase price delivered as cash — though the specifics of any individual deal are negotiated case by case and vary by practice profile.

The VSO vs. partnership model distinction

Within PE-backed buyers, there is a second layer of variation worth knowing about: the difference between a VSO model and a partnership or hybrid model.

A VSO — Veterinary Service Organization — is a consolidation model in which the buyer converts the selling practice owner into a salaried employee, taking full ownership of the practice. The seller gets cash at close, earns a salary going forward, and has no ongoing equity stake in the entity.

Octus’s 2025 sector research on private credit exposure to veterinary rollups found that VSO-structured platforms are showing the widest credit dispersion, with first-lien fair values ranging from 88 to 101 percent of par as of September 2025. Octus’s analysis cited the structural weakness of the VSO model — reduced doctor alignment and higher turnover relative to equity-sharing structures — as the driver.

That credit dispersion is worth understanding because it is a signal of operational stress that can affect how tightly these platforms run and what kind of post-close environment sellers step into.

The partnership-model buyers — those who preserve practice-level equity for the seller — are structurally designed to keep veterinarians more engaged post-close, because the seller’s remaining stake creates a shared interest in the practice’s performance.

---

The brand-handling question

This is the one sellers almost always ask once they understand the strategic-vs-PE distinction.

Mars Veterinary Health has a documented history of integrating acquired practices under its existing portfolio brands: VCA Animal Hospitals, Banfield, or BluePearl, depending on the acquisition type and the practice’s profile. That integration pattern is consistent with a strategic buyer‘s interest in building unified brand equity across a permanent portfolio.

PE-backed groups, in contrast, generally preserve the local practice name and branding across their portfolios. NVA, Mission Pet Health, VetCor, AmeriVet, PetVet, Thrive — all operate multi-hospital platforms where acquired practices continue to operate under their original names, with shared back-office infrastructure but visible local identity intact.

That happens partly because local brand equity is part of what they acquired and partly because rebranding hundreds of practices in dozens of markets is expensive and operationally complex.

I want to be direct on one point: brand handling is a negotiable and case-specific element in any deal. The patterns above describe general tendencies, not guarantees. The specific post-close terms governing your practice’s name, signage, and community identity are deal terms — they belong in the letter of intent and can be negotiated.

If local identity matters to you, that conversation should happen explicitly and early, not assumed based on buyer category.

---

What actually determines the price: competition, not category

Here’s what I’ve seen consistently in the processes I run: buyer category is not a price predictor. Competition is.

A direct offer from any buyer — strategic or PE-backed — reflects the leverage that buyer perceives in the conversation when they are the only party at the table. There is no competitive pressure forcing them to their best number.

The offer on day one of a direct, single-buyer conversation is rarely the offer you would receive if four qualified buyers were bidding simultaneously.

Capstone Partners‘ April 2026 Pet Sector M&A Update showed that YTD 2026 strategic activity has increased meaningfully — 10 strategic transactions versus 3 in the prior year. That uptick matters because more buyer types active simultaneously means more competition in a structured process. When the buyer pool includes both Mars (or strategic-aligned groups) and multiple PE-backed consolidators with different hold-period incentives, competitive tension across those groups can produce outcomes that no single-buyer conversation would reach.

The mechanics of this work through what we call the Elite Selling System — we hand-select and vet every buyer who gets to bid on your practice, the way a doorman with a velvet rope lets in only the right people, then run a private competitive bidding window inside that qualified pool. The filter is what creates the leverage that moves the number.

A seller who responds to one outreach call from one acquisition team and negotiates bilaterally has given that leverage away before the process starts.

We detail what to look for when deciding which buyer type fits your goals in our who-to-sell guide, and we break down how a practice gets valued before any buyer conversation in our practice valuation guide.

---

What sellers consistently get wrong about buyer categories

I want to name three patterns I see that tend to cost owners money or clarity.

Pattern 1: Treating buyer category as the main variable. The strategic-vs-PE distinction matters for post-close life. It is not, on its own, a pricing predictor.

Sellers who filter by buyer category before running a competitive process have already narrowed the buyer pool and reduced competitive pressure before they needed to.

Pattern 2: Underweighting the rollover and earnout math. When a buyer offers a headline multiple, the number that matters is how much of it you actually see, and when. A 13x multiple where 30 percent is rollover equity in a platform that may recapitalize in 4 years is a different economic proposition than a 10x multiple that is 85 percent cash at closing.

Learning to compare those two offers is not complicated, but it requires the right questions at the outset of the process.

Pattern 3: Not negotiating brand and operations terms explicitly. Post-close culture — who makes clinical decisions, what happens to staff, whether the practice name stays, how operations are integrated — matters to most sellers at least as much as the number. These terms are negotiable, and the time to negotiate them is before you sign the letter of intent, not after.

The full decision framework for choosing the right buyer type — beyond just strategic vs. PE — is at our sell my veterinary practice guide.

---

What to do from here

If you’re in the research phase — reading broadly, sizing up your options before you’ve committed to any path — the next step is understanding what your practice would actually clear in a 2026 competitive process. Not a range from an article.

The real number, based on your financials, your location, your staff depth, and your buyer profile.

That is what a practice value estimate is for.

The estimate is free. We look at your normalized EBITDA — what the practice earns in pure operating profit, before taxes and accounting choices — apply the multiple range relevant to your buyer pool and practice profile, and tell you what the competitive range looks like before any buyer conversation starts.

No commitment, no pressure. You leave with a number and a sense of which buyer categories are most likely to compete hardest for a practice like yours.

Start with a free, confidential practice value estimate.

Across the deals we’ve closed over the past four-plus years, the owners who got the best outcomes — across all buyer categories — started with a clear-eyed picture of what their practice was worth before the first buyer called. That picture is the foundation of everything.

The buyer type question becomes simpler once you know the range you should be negotiating from.

---

Frequently asked questions

What is the difference between a strategic and a private equity veterinary buyer in 2026?

A strategic buyer acquires veterinary practices as a permanent, long-term owner with no fixed exit plan. Mars Veterinary Health — owner of VCA, Banfield, and BluePearl — is the only major US strategic buyer.

A PE-backed buyer is funded by a private equity firm that must exit its investment within roughly 4 to 7 years, returning capital to investors through a sale, IPO, or recapitalization to another PE firm. That exit timeline shapes everything: how the buyer structures the deal, how aggressively they grow, and what happens to your rollover equity after the close.

Does a strategic buyer or a PE-backed buyer pay more for a veterinary practice?

Neither buyer category reliably pays more in every situation. What determines the outcome is whether you run a competitive process that puts multiple qualified buyers in the same bidding window.

The specific structure and terms of any offer — from any buyer type — only become visible and negotiable through competition. A single offer from any buyer, strategic or PE-backed, reflects the leverage that buyer perceives in the conversation.

Running a structured process with multiple bidders is what moves the number.

Will a strategic buyer like Mars rebrand my veterinary practice?

Mars Veterinary Health has a documented history of integrating acquired practices under its existing brands — VCA, Banfield, or BluePearl — depending on the acquisition type and practice profile. PE-backed groups, by contrast, generally preserve the local practice name and branding because they acquire practices across many different markets and a single unified rebrand is operationally complex.

Rebranding is a material post-close outcome for any seller concerned about their practice’s community identity, and it is worth examining when comparing strategic vs PE-backed offers.

What is a recapitalization and how does it affect sellers who retained rollover equity?

A recapitalization occurs when a PE-backed consolidator is sold from one private equity firm to another. The management team typically stays in place while ownership transfers to a new sponsor.

For sellers who retained rollover equity in the original deal, a recap is generally the first opportunity to convert that equity to cash. Sellers can either cash out at the recap or roll their equity into the new fund for another cycle.

The timeline and liquidity terms for a recap are negotiable at the time of the original sale and are worth addressing before you sign.

What deal structure differences should I expect from a PE-backed buyer vs a strategic buyer?

PE-backed buyers in the 2026 market commonly structure offers with a majority of value delivered as cash at closing, and the remainder split across earnout, rollover equity in the platform, and occasional seller notes. A growing subset of PE-backed groups offer partnership models where the seller retains 20 to 40 percent direct equity in their own practice entity with contractual buyout mechanics.

Strategic buyers like Mars tend to structure deals closer to all-cash acquisitions with less emphasis on rollover equity, reflecting their indefinite hold horizon and the lack of a fund exit to structure around.

How many strategic buyers are there in the US veterinary market in 2026?

In terms of major active acquirers, Mars Veterinary Health is the only large-scale strategic buyer operating in the US general-practice veterinary market in 2026. Every other significant acquirer — NVA (JAB Holdings), Mission Pet Health (Shore Capital), VetCor (Harvest Partners), PetVet Care Centers (Ares Management), AmeriVet (AEA Investors), Thrive Pet Healthcare (TSG Consumer Partners), and dozens more — is PE-backed and operates on a fund lifecycle with a defined exit requirement.

What is the VSO model and how does it differ from partnership-model PE buyers?

A VSO, or Veterinary Service Organization, is an acquisition model in which the consolidator converts the selling practice owner into a salaried employee, eliminating practice-level ownership. A partnership model, offered by a growing number of PE-backed groups, instead has the buyer acquire a majority stake in the practice while the seller retains 20 to 40 percent direct equity with a contractual put/call buyout date.

Octus’s 2025 sector research found that VSO-structured rollups are showing the widest credit dispersion, with fair values ranging from 88 to 101 percent of par, and that the structural weakness of the VSO model comes from reduced doctor alignment and higher turnover versus equity-sharing models.

How do I decide which buyer type is right for my veterinary practice?

The decision depends on what you want from life after the sale: how involved you want to stay, whether you want a second liquidity event through rollover equity, how important your practice’s name and community identity are, and how much certainty you need at closing. These questions are better answered after you have seen real offers from multiple buyer types side by side.

A competitive process surfaces the actual terms — not theoretical ones — and puts you in a position to compare what each buyer is genuinely willing to pay and how they want to structure the post-close relationship.

---

Sources

Industry M&A research and valuation data

1. Capstone Partners. “Pet Sector M&A Update — April 2026.” capstonepartners.com
2. Octus. “Private-Credit Exposure to Veterinary Rollups Shows Growing Dispersion; VSOs Under Increasing Pressure.” 2025. octus.com
3. Dechert LLP. “Dechert Sees Strong M&A and Private Equity Activity in Early 2026.” May 2026. dechert.com
4. Holland & Knight. “Q1 Recap on Proposed Legislation Affecting Healthcare Consolidation.” March 2026. hklaw.com

Public company and PE sponsor disclosures

5. Mission Pet Health. “Southern Veterinary Partners and Mission Veterinary Partners Join Together as Mission Pet Health.” Press release, July 21, 2025. missionpethealth.com
6. GlobeNewswire. “Southern Veterinary Partners and Mission Veterinary Partners Join Together as Mission Pet Health.” July 21, 2025. globenewswire.com
7. Shore Capital Partners. “Mission Pet Health — Portfolio.” shorecp.com
8. Harvest Partners. “VetCor Closes Recapitalization.” harvestpartners.com
9. JAB Holding Company. “Ares Management Agrees to Sell NVA.” Press release. jabholco.com
10. Mars, Incorporated. “Mars, Incorporated Completes Acquisition of VCA Inc.” PR Newswire. prnewswire.com
11. BusinessWire. “FCPT Announces Agreement to Acquire up to 102 Mission Pet Health Veterinary Properties for $268 Million.” May 2026. businesswire.com

Legal and regulatory analysis

12. Holland & Knight. “Up Next: Vet Clinic Acquisitions Targeted for Review and Approval in New York.” September 2025. hklaw.com